Human Anti-SFTSV Gn scFv-Fc Chimera (VS-0325-FY195) (CAT#: VS-0325-FY195)
Ab10 is a human monoclonal antibody specifically targeting the Gn glycoprotein of the SFTSV. It is engineered as an scFv fused to a human IgG1 Fc domain, providing enhanced stability and potential for therapeutic applications. This antibody was isolated from a phage-displayed library constructed from a patient who recovered from SFTS, indicating its potential for neutralizing the virus.
Specific Inquiry
Custom Production
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
We require custom production
Specifications
- Immunogen
- SFTSV Gn glycoprotein (specifically, the extracellular domain comprising all ten lectin-binding domains fused with a human IgG Fc domain).
- Host Species
- Human
- Type
- Human IgG1, scFv-Fc
- Specificity
- Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Gn
- Species Reactivity
- Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)
- Applications
- Western Blot, ELISA, Immunofluorescence, Neutralization
Product Property
- Purity
- >95% as determined by SDS-PAGE
- Concentration
- Please refer to the vial label for the specific concentration.
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
- Shipping
- Ice packs
Target
- Alternative Names
- Severe Fever with Thrombocytopenia Syndrome Virus Glycoprotein N; SFTSV Gn
- Long Name
- Severe Fever with Thrombocytopenia Syndrome Virus Glycoprotein N
- Function
- SFTSV Gn refers to the glycoprotein N of Severe Fever with Thrombocytopenia Syndrome Virus, which is involved in viral entry and is a target for neutralizing antibodies. It is a key component in the virus's ability to infect host cells.
Recommended Products
Isotype Control
Secondary Antibody
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "SFTSV GN"
Select a product category from the dropdown menu below to view related products.
Please select product type
IgG Antibody Products
Fab Antibody Products
ScFv Antibody Products
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABC-478 | Recombinant Human Anti-SFTSV GN Antibody (MAb4-5) | Neut, SPR, IF, ELISA, WB | Human IgG1, κ |
| HPAB-M0508-YC | Human Anti-SFTSV Gn Recombinant Antibody (HPAB-M0508-YC) | ELISA, Neut | Human IgG |
| HPAB-M0509-YC | Human Anti-SFTSV Gn Recombinant Antibody (HPAB-M0509-YC) | ELISA, IF, Neut | Human IgG |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-0325-FY195. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: FC, Cyt, Stim, PP, Agonist
Application: WB, ELISA, IP, FC, FuncS, Neut, IF
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
-2.png)
Application: IB, ELISA, FC, FuncS
Application: ELISA, WB, Neut, Funcs, IHC, Inhib
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, FC, WB, Inhib, IHC
Application: ELISA, FC, FuncS
Application: WB, IHC-Fr, IHC-P, ICC, IF
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
